Gastroenterology

  • Home
  • Gastroenterology
Headache Relief Shampoo Voted #1 Best New Product in 2019

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019 / by / in
A Safety Study of SGN-TGT (SEA-TGT) in Patients With Advanced Cancer
Conditions:   Non-small Cell Lung Cancer;   Gastric Carcinoma;   Classical Hodgkin Lymphoma;   Diffuse Large B-cell Lymphoma;   Peripheral T-cell Lymphoma
Interventions:   Drug: SGN-TGT;   Drug: pembrolizumab
Sponsor:   Seattle Genetics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 10, 2020 / by / in
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Conditions:   Non-small Cell Lung Cancer;   Breast Cancer;   Gastric Cancer;   Renal Cell Carcinoma;   Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer;   Cholangiocarcinoma;   Bladder Urothelial Carcinoma;   MSI-H Colorectal Cancer;   Esophageal Cancer;   Hepatic Cancer;   Head and Neck Cancer;   Other Solid Tumors
Intervention:   Drug: CDX-527
Sponsor:   Celldex Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 8, 2020 / by / in
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia
Condition:   Oropharyngeal Dysphagia
Intervention:   Drug: Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)
Sponsors:   Peter Belafsky, MD;   Cook MyoSite
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 3, 2020 / by / in
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Conditions:   Bladder Cancer;   Gastric Cancer;   Non Small Cell Lung Cancer;   NSCLC;   Urothelial Carcinoma;   Advanced Solid Tumor
Intervention:   Drug: APR-246 (eprenetapopt) + Pembrolizumab
Sponsor:   Aprea Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 2, 2020 / by / in
Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Conditions:   Prevention of Esophageal Varices;   NASH – Nonalcoholic Steatohepatitis;   Cirrhosis
Interventions:   Drug: belapectin;   Drug: Placebo
Sponsor:   Galectin Therapeutics Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2020 / by / in
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03)
Condition:   Gastric Cancer
Interventions:   Drug: Fluorouracil (5-FU);   Drug: Capecitabine;   Biological: Durvalumab;   Drug: Oxaliplatin;   Biological: Trastuzumab;   Drug: Trastuzumab deruxtecan;   Drug: Cisplatin
Sponsors:   AstraZeneca;   Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 26, 2020 / by / in
Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma
Conditions:   Advanced Gastroesophageal Junction Adenocarcinoma;   Clinical Stage III Esophageal Adenocarcinoma AJCC v8;   Clinical Stage III Gastric Cancer AJCC v8;   Clinical Stage IV Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Gastroesophageal Junction Adenocarcinoma;   Metastatic Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage III Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage III Gastric Cancer AJCC v8;   Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Gastric Cancer AJCC v8;   Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Gastric Cancer AJCC v8;   Pathologic Stage IIIC Gastric Cancer AJCC v8;   Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IV Gastric Cancer AJCC v8;   Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8;   Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8;   Unresectable Gastroesophageal Junction Adenocarcinoma
Intervention:   Biological: Pembrolizumab
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 23, 2020 / by / in
Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer
Condition:   Gastric and Gastroesophageal Junction Cancer
Intervention:   Drug: AMG 199
Sponsor:   Amgen
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 19, 2020 / by / in
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Conditions:   Locally Advanced Solid Tumor;   Metastatic Cancer;   Solid Tumor;   HER2-positive Gastric Cancer;   HER2-positive Metastatic Breast Cancer
Interventions:   Drug: ACE1702;   Drug: Cyclophosphamide;   Drug: Fludarabine
Sponsor:   Acepodia Biotech Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 19, 2020 / by / in
P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric
Conditions:   Esophageal Adenocarcinoma;   Gastric Adenocarcinoma
Interventions:   Drug: Nal-IRI;   Drug: Oxaliplatin;   Drug: 5-FU;   Drug: Trastuzumab
Sponsors:   University of Wisconsin, Madison;   Ipsen
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 19, 2020 / by / in